In the HIMALAYA trial of 305 people with ALS in 13 countries, the RIPK1 inhibitor SAR443820 did not slow functional decline over 24 weeks and caused more liver enzyme increases than placebo.
In the HEALEY ALS Platform Trial, 325 participants took DNL343 or placebo for 24 weeks. The drug, which targets the cell's integrated stress response, did not slow loss of function or improve survival.
A study published Oct. 27, 2026, in Nature Medicine found that in ALS, more T cells in the spinal fluid went with slower progression, while more activated T cells in the blood went with faster progression. Signs of cytomegalovirus immunity…